Telomir Pharmaceuticals Announces Breakthrough Results With Telomir-1 Fully Reversing Oxidative Stress in Human Cell Lines and Exploring Potential as a Treatment for Avian Influenza (Bird Flu) and Other Viruses
Telomir Pharmaceuticals (NASDAQ:TELO) announced breakthrough results from preclinical studies showing Telomir-1's ability to fully reverse copper-induced elevation of Reactive Oxygen Species (ROS) and protect cells against copper toxicity in human cell lines. The compound demonstrated effectiveness at doses significantly lower than copper levels, indicating a unique regulatory mechanism beyond copper ion chelation.
The company is exploring Telomir-1's potential applications across multiple conditions where oxidative stress plays a important role, including Wilson's Disease, Alzheimer's, Age-related Macular Degeneration (AMD), cancer, and cardiovascular diseases. Additionally, Telomir is investigating the compound's potential as a treatment for viral infections, particularly avian influenza (bird flu), which has infected over 868 people globally with a 50% mortality rate according to WHO.
The research shows Telomir-1's ability to normalize ROS levels and provide cellular protection, positioning it as a promising therapeutic candidate for addressing oxidative stress-related pathologies and viral infections.
Telomir Pharmaceuticals (NASDAQ:TELO) ha annunciato risultati rivoluzionari da studi preclinici che mostrano la capacità di Telomir-1 di annullare completamente l'elevazione delle specie reattive dell'ossigeno (ROS) indotta dal rame e di proteggere le cellule contro la tossicità del rame in linee cellulari umane. Il composto ha dimostrato efficacia a dosi significativamente inferiori ai livelli di rame, indicando un meccanismo di regolazione unico oltre alla chelazione degli ioni di rame.
L'azienda sta esplorando le potenziali applicazioni di Telomir-1 in diverse condizioni in cui lo stress ossidativo gioca un ruolo importante, inclusi la malattia di Wilson, l'Alzheimer, la degenerazione maculare legata all'età (AMD), il cancro e le malattie cardiovascolari. Inoltre, Telomir sta investigando il potenziale del composto come trattamento per le infezioni virali, in particolare l'influenza aviaria (influenza aviare), che ha infettato oltre 868 persone in tutto il mondo con un tasso di mortalità del 50% secondo l'OMS.
La ricerca mostra la capacità di Telomir-1 di normalizzare i livelli di ROS e fornire protezione cellulare, posizionandolo come un promettente candidato terapeutico per affrontare le patologie correlate allo stress ossidativo e le infezioni virali.
Telomir Pharmaceuticals (NASDAQ:TELO) anunció resultados innovadores de estudios preclínicos que muestran la capacidad de Telomir-1 para revertir completamente la elevación de las Especies Reactivas de Oxígeno (ROS) inducida por el cobre y proteger a las células contra la toxicidad del cobre en líneas celulares humanas. El compuesto demostró eficacia a dosis significativamente inferiores a los niveles de cobre, lo que indica un mecanismo regulador único más allá de la quelación de iones de cobre.
La empresa está explorando las posibles aplicaciones de Telomir-1 en múltiples condiciones donde el estrés oxidativo juega un papel importante, incluyendo la enfermedad de Wilson, el Alzheimer, la Degeneración Macular Relacionada con la Edad (AMD), el cáncer y las enfermedades cardiovasculares. Además, Telomir está investigando el potencial del compuesto como tratamiento para infecciones virales, particularmente la influenza aviar, que ha infectado a más de 868 personas en todo el mundo con una tasa de mortalidad del 50% según la OMS.
La investigación muestra la capacidad de Telomir-1 para normalizar los niveles de ROS y proporcionar protección celular, posicionándolo como un candidato terapéutico prometedor para abordar las patologías relacionadas con el estrés oxidativo y las infecciones virales.
텔로미르 제약 (NASDAQ:TELO)는 텔로미르-1이 구리에 의해 유도된 반응성 산소종(ROS)의 상승을 완전히 역전시키고 인체 세포주에서 구리 독성으로부터 세포를 보호할 수 있는 능력을 보여주는 전임상 연구의 획기적인 결과를 발표했습니다. 이 화합물은 구리 수준보다 상당히 낮은 용량에서도 효과를 나타내어 구리 이온 킬레이트 외의 독특한 조절 메커니즘을 시사합니다.
회사는 텔로미르-1의 산화 스트레스가 중요한 역할을 하는 다양한 질환에서의 잠재적 응용 가능성을 탐색하고 있으며, 윌슨병, 알츠하이머, 노인성 황반변성(AMD), 암 및 심혈관 질환을 포함합니다. 또한 텔로미르는 이 화합물이 특히 세계적으로 868명 이상에 감염되어 50%의 사망률을 기록한 조류 인플루엔자와 같은 바이러스 감염 치료제로서의 잠재력을 조사하고 있습니다.
연구 결과는 텔로미르-1이 ROS 수준을 정상화하고 세포 보호를 제공할 수 있는 능력을 보여주며, 산화 스트레스 관련 질환 및 바이러스 감염을 해결하기 위한 유망한 치료 후보로 자리 잡고 있음을 입증합니다.
Telomir Pharmaceuticals (NASDAQ:TELO) a annoncé des résultats majeurs issus d'études précliniques montrant la capacité de Telomir-1 à inverser complètement l'élévation des espèces réactives de l'oxygène (ROS) induite par le cuivre et à protéger les cellules contre la toxicité du cuivre dans des lignées cellulaires humaines. Le composé a démontré son efficacité à des doses significativement inférieures aux niveaux de cuivre, indiquant un mécanisme de régulation unique au-delà de la chélation des ions de cuivre.
L'entreprise explore les applications potentielles de Telomir-1 dans plusieurs conditions où le stress oxydatif joue un rôle important, y compris la maladie de Wilson, Alzheimer, la dégénérescence maculaire liée à l'âge (AMD), le cancer et les maladies cardiovasculaires. De plus, Telomir enquête sur le potentiel du composé en tant que traitement pour les infections virales, en particulier la grippe aviaire, qui a infecté plus de 868 personnes dans le monde, avec un taux de mortalité de 50 % selon l'OMS.
La recherche montre la capacité de Telomir-1 à normaliser les niveaux de ROS et à fournir une protection cellulaire, le positionnant comme un candidat thérapeutique prometteur pour traiter les pathologies liées au stress oxydatif et les infections virales.
Telomir Pharmaceuticals (NASDAQ:TELO) hat bahnbrechende Ergebnisse aus präklinischen Studien veröffentlicht, die die Fähigkeit von Telomir-1 zeigen, die durch Kupfer induzierte Erhöhung der reaktiven Sauerstoffspezies (ROS) vollständig zurückzudrängen und Zellen gegen Kupfertoxizität in menschlichen Zelllinien zu schützen. Die Verbindung zeigte Wirksamkeit bei signifikant niedrigeren Dosen als Kupferwerte, was auf einen einzigartigen Regulationsmechanismus jenseits der Kupferionen-Chelatbildung hinweist.
Das Unternehmen untersucht die potenziellen Anwendungsgebiete von Telomir-1 in mehreren Erkrankungen, bei denen oxidativer Stress eine wichtige Rolle spielt, darunter Wilson-Krankheit, Alzheimer, altersbedingte Makuladegeneration (AMD), Krebs und Herz-Kreislauf-Erkrankungen. Zusätzlich erforscht Telomir das Potenzial der Verbindung als Behandlung für Virusinfektionen, insbesondere die Vogelgrippe, die laut WHO über 868 Menschen weltweit infiziert hat und eine Sterblichkeitsrate von 50% aufweist.
Die Forschung zeigt die Fähigkeit von Telomir-1, ROS-Spiegel zu normalisieren und zellulären Schutz bereitzustellen, wodurch es als vielversprechender therapeutischer Kandidat zur Bekämpfung von oxidativem Stress und virusbedingten Erkrankungen positioniert wird.
- Successful preclinical results showing full reversal of oxidative stress in human cell lines
- Demonstrated effectiveness at low doses, indicating efficient regulatory mechanism
- Potential applications across multiple major diseases including Alzheimer's, AMD, cancer
- Possible application in treating bird flu, addressing a $1B+ government-funded market
- Still in preclinical stage, requiring further studies and regulatory approvals
- No proven efficacy in human subjects yet
- Faces competition in multiple therapeutic areas
Insights
The breakthrough results from Telomir-1's preclinical studies represent a significant scientific advancement with broad therapeutic implications. The compound's demonstrated ability to fully reverse copper-induced ROS elevation and provide cellular protection is particularly noteworthy for several reasons:
First, the compound's efficacy at doses significantly lower than copper levels indicates a unique regulatory mechanism beyond simple chelation. This suggests potential superior safety profile compared to existing treatments for conditions like Wilson's Disease, where current therapies often carry severe side effects.
The market opportunity spans multiple high-value indications:
- Wilson's Disease: A rare disease affecting 1 in 30,000 people globally, qualifying for orphan drug designation and expedited regulatory pathways
- Alzheimer's Disease: A market projected to reach $5.7 billion by 2027, with few effective treatments available
- AMD: Growing prevalence due to aging populations, with current treatments focused on symptoms rather than underlying causes
- Viral applications: The potential role in treating avian influenza addresses a critical unmet need, supported by $1 billion+ in government funding
The compound's broad therapeutic potential could significantly expand Telomir's addressable market. The exploration of antiviral applications, particularly for avian influenza with its 50% mortality rate, positions the company to address emerging public health threats.
What sets this development apart is the compound's novel mechanism of action and potential for oral administration, which could offer significant advantages over existing treatments. The preclinical data suggests a favorable safety profile, though this will need validation in human trials.
This breakthrough carries substantial intellectual property implications that could significantly enhance Telomir's market position. The novel regulatory mechanism of Telomir-1, operating at doses below copper levels, suggests a unique mode of action that strengthens patentability claims. This differentiation from traditional chelation approaches could support broad patent protection across multiple therapeutic applications.
The compound's versatility across different indications - from rare diseases to widespread conditions and viral infections - creates multiple layers of patent protection opportunities. This could include:
- Composition of matter patents for the compound
- Method-of-use patents for specific disease applications
- Formulation patents for various delivery methods
- Treatment protocol patents for combination therapies
The expansion into viral applications, particularly for avian influenza, opens additional patenting opportunities in an area with significant government interest and funding support. This diversification of IP assets reduces risk and increases potential licensing revenue streams.
Oxidative stress drives aging and is a key factor in diseases like Alzheimer's, Age-related Macular Degeneration (AMD), cardiovascular diseases, cancer, and diabetes. It also plays a critical role in the progression of viral infections, such as avian influenza (bird flu), by exacerbating inflammation and cellular damage. Directly addressing oxidative stress and its consequences is essential to treating the underlying causes of these conditions and mitigating the severity of viral outbreaks.
MIAMI, FLORIDA / ACCESS Newswire / January 28, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or Telomir, a leader in age-reversal science, today announced groundbreaking results from its recent preclinical studies conducted in human cell lines. These studies demonstrated the ability of Telomir-1 to fully reverse copper-induced elevation of Reactive Oxygen Species (ROS) and provide robust cellular protection against copper toxicity.
"The results of our studies demonstrate the exceptional potential of Telomir-1 in addressing oxidative stress and its related pathologies," said Raphael Mayer, Ph.D., Founder and CEO of Smart Assays Biotechnologies Ltd. "Telomir-1's ability to fully normalize copper-induced ROS and to protect the cells from damage represents a significant leap forward in our understanding of this compound's therapeutic potential."
Oxidative stress occurs when there is an imbalance between free radicals and antioxidants in the body. This imbalance leads to the generation of harmful ROS, which can damage cellular structures, including DNA, mitochondria, proteins, and lipids. It plays a central role in the progression of diseases such as Alzheimer's, AMD, cancer, cardiovascular conditions, and diabetes. Furthermore, oxidative stress accelerates telomere shortening, compromising cellular repair mechanisms and contributing to aging and disease development.
In the context of viral infections, such as avian influenza (bird flu), oxidative stress is a key factor in disease severity. Viral infections trigger and exploit excessive ROS production as a mode to facilitate their replication, leading to widespread inflammation, cellular damage, and impaired immune responses. This oxidative damage exacerbates disease progression and increases the risk of severe outcomes. Addressing oxidative stress in viral infections is critical for mitigating these effects and improving patient recovery.
Telomir-1's potential ability to shield cells from copper toxicity is particularly significant in diseases linked to copper dysregulation. Conditions such as Wilson's disease, AMD, and Alzheimer's disease are directly affected by excess copper, which exacerbates oxidative stress and cellular damage. By mitigating copper toxicity, Telomir-1 offers a targeted approach to protecting cellular health and addressing the root causes of these debilitating diseases.
Erez Aminov, Chairman and CEO of Telomir, added, "With its unique regulatory mechanism and broad application, Telomir-1 is more than a single treatment-it is a platform that could potentially transform healthcare for millions. In addition to addressing age-related diseases, we are exploring its role in combating oxidative stress in viral infections such as avian influenza (bird flu). The urgent need for effective treatments underscores the importance of Telomir-1 in reducing the severe effects of oxidative stress during outbreaks. Our mission is to leverage its capabilities to address unmet medical needs and improve patient outcomes worldwide.
Key findings from the study include:
Reversal of Oxidative Stress: Telomir-1 has potential to fully normalize ROS levels, effectively reversing oxidative damage in human cell lines.
Cellular Protection: Telomir-1 provided strong protection against copper-induced toxicity while maintaining cellular integrity.
Regulatory Mechanism: Telomir-1 demonstrated effects at doses significantly lower than copper levels, indicating its unique regulatory mechanism beyond copper ion chelation.
Dr. Itzchak Angel, Chief Scientific Advisor at Telomir, commented, "These findings underscore the unique profile of Telomir-1 as an intracellular regulator of oxidative stress. Its ability to act at low doses, rather than as a chelator, to reverse copper-induced ROS and toxicity positions it as a promising candidate for multiple indications, including neurodegeneration and metabolic disorders."
Transformative Potential for Wilson's Disease, Alzheimer's, AMD, Cancer, and Cardiovascular Diseases
Wilson's Disease: A rare genetic disorder caused by excessive copper accumulation, affecting approximately 1 in 30,000 people globally. Current treatments come with severe side effects, but Telomir-1's ability to regulate copper metabolism and normalize ROS presents a promising alternative to address the root causes of the disease while minimizing adverse effects.
Alzheimer's Disease: Oxidative stress, particularly the one associated with copper, contributes to neurodegeneration, protein misfolding and aggregation, and subsequent cognitive decline. By reversing the oxidative damage, Telomir-1 offers the potential to slow or halt disease progression and improve patient outcomes.
Age-related Macular Degeneration (AMD): Oxidative stress is a major driver of retinal damage and vision loss in AMD. Telomir-1's protective effects on cells could provide a novel approach to preserving vision and addressing the underlying causes of this condition.
Cancer: Oxidative stress fuels DNA damage, tumor growth, and resistance to treatments like chemotherapy. Telomir-1's ability to reverse ROS damage positions it as a potential adjunct to improve cancer therapies and patient survival rates.
Cardiovascular Diseases: Oxidative stress impairs vascular function, accelerates atherosclerosis, ischemic conditions, and exacerbates chronic inflammation. Telomir-1's regulatory effects could protect cardiovascular health and reduce the risk of these conditions.
Telomir-1's ability to reverse oxidative damage and protect cells highlights its transformative potential across these diseases, offering innovative solutions to improve patient care.
Future Exploration: Oxidative Stress and Viruses, Including Avian Influenza (Bird Flu)
Telomir is also exploring the application of Telomir-1 as an oral treatment for oxidative stress caused by viral infections, including emerging threats such as avian influenza (bird flu). The bird flu has infected over 868 people globally as of 2023, with a mortality rate of approximately
This zoonotic virus is characterized by severe inflammation and elevated oxidative stress, both of which contribute to rapid disease progression and organ damage. Currently, there are no approved drugs specifically targeting the oxidative stress caused by the bird flu or similar viruses. Telomir-1's ability to reverse oxidative stress and protect cells offers a promising avenue for addressing this gap. By mitigating the cellular damage associated with oxidative stress, Telomir-1 has the potential to play a critical role in reducing the severity of such infections. This represents a key area of future investigation for Telomir.
About Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) is a pre-clinical stage pharmaceutical company seeking to lead development in several areas, including age-reversal science. Telomir is focused on the development of Telomir-1, a novel small molecule metal ion regulator designed to lengthen the DNA's protective telomere caps, which are crucial in the aging process. Telomir's goal is to explore the potential of Telomir-1 starting with ongoing research in animals and then in humans.
Telomeres are the protective end caps of a chromosome made up of DNA sequences and proteins. As humans age, telomeres shorten, with metal reactivity accelerating the process, which presents humans and pet animals with an increased chance of contracting a number of degenerative and age-related diseases. Telomir's goal is to develop and gain regulatory approval for Telomir-1, proposed to be dosed orally, with the broader aim of promoting longevity and enhancing overall quality of life.
Telomir-1 is in preclinical development and has not yet been tested in humans. There is no assurance that Telomir-1 will proceed through development or will ultimately receive FDA approval for marketing.
Cautionary Note Regarding Forward-Looking Statements
This press release, statements of Telomir Pharmaceuticals' management or advisors related thereto, and the statements contained in the news story linked in this release contain "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements.
These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications, and the safety of Telomir-1.
Contact Information
Helga Moya
info@telomirpharma.com
(786) 396-6723
SOURCE: Telomir Pharmaceuticals, Inc
View the original press release on ACCESS Newswire
FAQ
What are the key findings of Telomir-1's preclinical studies announced in January 2025?
What diseases could Telomir-1 (TELO) potentially treat based on the latest research?
How does Telomir-1's mechanism of action work against oxidative stress?
What is TELO's potential role in treating avian influenza (bird flu)?
